Our services
Integrated Decision-Making Across the Development Journey
At Esylos, every engagement starts from the same place: the decision that needs to be made, and what it will take to make it with confidence in the face of uncertainty.
We partner with your team to enable informed decision-making when the path forward is unclear, data is incomplete, and the cost of being wrong is high.
[01]
Development Strategy & Decision Support
Integrating knowledge from the earliest development stage and continuously building a causal graph as evidence accumulates allows teams to see the whole program and make decisions that account for downstream consequences.
Open
Close
Core capabilities
Causal AI for decision-making under uncertainty
Expert knowledge mapping and elicitation
Risk-centric development planning
[02]
Innovative Clinical Development
Our experts bring a proven track record of innovative trial design and published methods to help teams design optimal studies that deliver results faster and at lower cost without sacrificing rigor or regulatory acceptance.
Open
Close
Core capabilities
Rare disease trial design and execution
Bayesian adaptive clinical designs
Real-world evidence integration and regulatory strategy
[03]
CMC Statistics & Decision Support
Esylos brings causal reasoning, Bayesian decision support, and deep CMC expertise to help life science teams make confident manufacturing decisions — from process characterization through commercial distribution.
Open
Close
Core capabilities
Regulatory-ready CMC across the full lifecycle
DoE & Bayesian optimization for process understanding
Causal reasoning & digital twins for manufacturing decisions
[01]
Development Strategy & Decision Support
Integrating knowledge from the earliest development stage and continuously building a causal graph as evidence accumulates allows teams to see the whole program and make decisions that account for downstream consequences.
Open
Close
Core capabilities
Causal AI for decision-making under uncertainty
Expert knowledge mapping and elicitation
Risk-centric development planning
[02]
Innovative Clinical Development
Our experts bring a proven track record of innovative trial design and published methods to help teams design optimal studies that deliver results faster and at lower cost without sacrificing rigor or regulatory acceptance.
Open
Close
Core capabilities
Rare disease trial design and execution
Bayesian adaptive clinical designs
Real-world evidence integration and regulatory strategy
[03]
CMC Statistics & Decision Support
Esylos brings causal reasoning, Bayesian decision support, and deep CMC expertise to help life science teams make confident manufacturing decisions — from process characterization through commercial distribution.
Open
Close
Core capabilities
Regulatory-ready CMC across the full lifecycle
DoE & Bayesian optimization for process understanding
Causal reasoning & digital twins for manufacturing decisions
Why this matters
When CMC statistics operates in isolation from development strategy, the consequences are predictable: specifications disconnected from clinical relevance, validation strategies that miss the real process risks, design spaces that break at scale, and stability models that create false confidence. These are the issues behind many CMC-related regulatory setbacks — and most are not failures of statistical technique. They are failures of connection between data, decisions, and regulatory argumentation.
Why this matters
When CMC statistics operates in isolation from development strategy, the consequences are predictable: specifications disconnected from clinical relevance, validation strategies that miss the real process risks, design spaces that break at scale, and stability models that create false confidence. These are the issues behind many CMC-related regulatory setbacks — and most are not failures of statistical technique. They are failures of connection between data, decisions, and regulatory argumentation.
Why this matters
When CMC statistics operates in isolation from development strategy, the consequences are predictable: specifications disconnected from clinical relevance, validation strategies that miss the real process risks, design spaces that break at scale, and stability models that create false confidence. These are the issues behind many CMC-related regulatory setbacks — and most are not failures of statistical technique. They are failures of connection between data, decisions, and regulatory argumentation.
How can we help you achieve your goals?
Describe your challenges

How can we help you achieve your goals?
Describe your challenges

How can we help you achieve your goals?
Describe your challenges
